Updated results of the placebo‐controlled, phase III JAKARTA trial of fedratinib in patients with intermediate‐2 or high‐risk myelofibrosis

Added 54 days ago (31.07.2021)
Authors: Animesh Pardanani, Ayalew Tefferi, Tamás Masszi, Elena Mishchenko, Mark Drummond, Eric Jourdan, Alessandro Vannucchi, Mindaugas Jurgutis, Vincent Ribrag, Alessandro Rambaldi, Liang Piu Koh, Shelonitda Rose, Jun Zhang, Claire Harrison
Read article